Loading...
XNASATRA
Market cap76mUSD
Dec 24, Last price  
13.29USD
1D
8.93%
1Q
79.59%
Jan 2017
-96.26%
IPO
-95.57%
Name

Atara Biotherapeutics Inc

Chart & Performance

D1W1MN
XNAS:ATRA chart
P/E
—
P/S
8.93
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-24.72%
Rev. gr., 5y
%
Revenues
9m
-86.51%
00000000020,340,00063,573,0008,573,000
Net income
-276m
L-87.91%
-123,300,000-87,730,000-280,060,000-572,210,000-790,490,000-1,194,910,000-2,306,990,000-2,909,760,000-3,066,200,000-3,401,410,000-2,283,020,000-276,126,000
CFO
-193m
L-28.64%
-2,475,000-5,966,000-16,628,000-37,156,000-60,025,000-87,502,000-179,772,000-235,626,000-180,759,000-220,522,000-270,430,000-192,977,000
Earnings
Mar 26, 2025

Profile

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
URL
https://www.atarabio.com/
IPO date
Oct 16, 2014
Employees
317
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
8,573
-86.51%
63,573
212.55%
20,340
 
Cost of revenue
283,468
358,654
372,182
Unusual Expense (Income)
NOPBT
(274,895)
(295,081)
(351,842)
NOPBT Margin
Operating Taxes
15
12
46
Tax Rate
NOPAT
(274,910)
(295,093)
(351,888)
Net income
(276,126)
-87.91%
(2,283,020)
-32.88%
(3,401,410)
10.93%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,136
23,189
104,215
BB yield
-98.32%
-17.33%
-17.65%
Debt
Debt current
12,179
13,640
2,753
Long-term debt
91,386
116,128
51,036
Deferred revenue
37,562
77,000
55,708
Other long-term liabilities
39,254
35,800
1,501
Net debt
51,840
(113,051)
(318,479)
Cash flow
Cash from operating activities
(192,977)
(270,430)
(220,522)
CAPEX
(1,223)
(4,193)
(10,580)
Cash from investing activities
123,866
202,956
22,258
Cash from financing activities
2,010
53,084
103,944
FCF
(231,201)
(289,476)
(369,007)
Balance
Cash
51,725
242,819
371,068
Long term investments
1,200
Excess cash
51,296
239,640
371,251
Stockholders' equity
(1,969,343)
(1,695,081)
(1,465,081)
Invested Capital
2,004,800
2,006,225
1,830,175
ROIC
ROCE
EV
Common stock shares outstanding
4,236
40,796
37,468
Price
0.51
-84.37%
3.28
-79.19%
15.76
-19.71%
Market cap
2,172
-98.38%
133,811
-77.34%
590,496
1.66%
EV
54,012
20,760
272,017
EBITDA
(270,066)
(289,428)
(342,497)
EV/EBITDA
Interest
5,285
1,986
Interest/NOPBT